FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801456890> ?p ?o ?g. }

• W2801456890 abstract "Extranodal NK/T-cell lymphoma (ENKTCL) is a highly aggressive mature NK/T-cell neoplasm marked by NK-cell phenotypic expression of CD3ε and CD56. While the disease is reported worldwide, there is a significant geographic variation with its highest incidence in East Asian countries possibly related to the frequent early childhood exposure of Epstein-Barr virus (EBV) and specific ethnic-genetical background, which contributes to the tumorigenesis. Historically, anthracycline-based chemotherapy such as CHOP (cyclophosphamide, adriamycin, vincristine, and prednisone) was used, but resulted in poor outcomes. This is due in part to intrinsic ENKTCL resistance to anthracycline caused by high expression levels of P-glycoprotein. The recent application of combined modality therapy with concurrent or sequential radiation therapy for early stage disease, along with non-anthracycline-based chemotherapy regimens consisting of drugs independent of P-glycoprotein have significantly improved clinical outcomes. Particularly, this neoplasm shows high sensitivity to l-asparaginase as NK-cells lack asparagine synthase activity. Even still, outcomes of patients with advanced stage disease or those with relapsed/recurrent disease are dismal with overall survival of generally a few months. Thus, novel therapies are needed for this population. Clinical activity of targeted antibodies along with antibody-drug conjugates, such as daratumumab (naked anti-CD38 antibody) and brentuximab vedotin (anti-CD30 antibody conjugated with auristatin E), have been reported. Further promising data have been shown with checkpoint inhibitors as high levels of programmed death-ligand 1 expression are observed in ENKTCL due to EBV-driven overexpression of the latent membrane proteins [latent membrane protein 1 (LMP1) and LMP2] with activation of the NF-κB/MAPK pathways. Initial case series with programmed death 1 inhibitors showed an overall response rate of 100% in seven relapsed patients including five with a complete response (CR). Furthermore, cellular immunotherapy with engineered cytotoxic T lymphocytes targeted against LMP1 and LMP2 have shown encouraging results with durable CRs as either maintenance therapy after initial induction chemotherapy or in the relapsed/refractory setting. In this paper, we review this exciting field of novel immunotherapy options against ENKTCL that hopefully will change the treatment paradigm in this deadly disease." @default.
• W2801456890 created "2018-05-17" @default.
• W2801456890 creator A5024273516 @default.
• W2801456890 creator A5037784199 @default.
• W2801456890 date "2018-04-30" @default.
• W2801456890 modified "2023-09-30" @default.
• W2801456890 title "Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma" @default.
• W2801456890 cites W1490393470 @default.
• W2801456890 cites W1521547106 @default.
• W2801456890 cites W1538565046 @default.
• W2801456890 cites W1590827989 @default.
• W2801456890 cites W1938402249 @default.
• W2801456890 cites W1974717295 @default.
• W2801456890 cites W1983062149 @default.
• W2801456890 cites W1993732758 @default.
• W2801456890 cites W1993825910 @default.
• W2801456890 cites W2006122340 @default.
• W2801456890 cites W2009607549 @default.
• W2801456890 cites W2012521762 @default.
• W2801456890 cites W2032713012 @default.
• W2801456890 cites W2035804591 @default.
• W2801456890 cites W2040724113 @default.
• W2801456890 cites W2054344525 @default.
• W2801456890 cites W2056505720 @default.
• W2801456890 cites W2060466778 @default.
• W2801456890 cites W2062486240 @default.
• W2801456890 cites W2063423717 @default.
• W2801456890 cites W2064565700 @default.
• W2801456890 cites W2069720281 @default.
• W2801456890 cites W2071270987 @default.
• W2801456890 cites W2073833526 @default.
• W2801456890 cites W2080873028 @default.
• W2801456890 cites W2090821308 @default.
• W2801456890 cites W2100106580 @default.
• W2801456890 cites W2101740016 @default.
• W2801456890 cites W2101879498 @default.
• W2801456890 cites W2105446032 @default.
• W2801456890 cites W2120020619 @default.
• W2801456890 cites W2134315181 @default.
• W2801456890 cites W2139891818 @default.
• W2801456890 cites W2141502099 @default.
• W2801456890 cites W2144855008 @default.
• W2801456890 cites W2145174107 @default.
• W2801456890 cites W2147240268 @default.
• W2801456890 cites W2148176898 @default.
• W2801456890 cites W2154269623 @default.
• W2801456890 cites W2155256323 @default.
• W2801456890 cites W2156762984 @default.
• W2801456890 cites W2167179373 @default.
• W2801456890 cites W2224015809 @default.
• W2801456890 cites W2225827478 @default.
• W2801456890 cites W2264394109 @default.
• W2801456890 cites W2289474065 @default.
• W2801456890 cites W2310716991 @default.
• W2801456890 cites W239460219 @default.
• W2801456890 cites W2439803058 @default.
• W2801456890 cites W2512106959 @default.
• W2801456890 cites W2513177163 @default.
• W2801456890 cites W2524224963 @default.
• W2801456890 cites W2528329272 @default.
• W2801456890 cites W2529923789 @default.
• W2801456890 cites W2530394087 @default.
• W2801456890 cites W2537909502 @default.
• W2801456890 cites W2547310148 @default.
• W2801456890 cites W2586276931 @default.
• W2801456890 cites W2603029028 @default.
• W2801456890 cites W2606016578 @default.
• W2801456890 cites W2612422733 @default.
• W2801456890 cites W2623658063 @default.
• W2801456890 cites W2743083943 @default.
• W2801456890 cites W2752993654 @default.
• W2801456890 cites W2754794784 @default.
• W2801456890 cites W2765652199 @default.
• W2801456890 cites W2766046670 @default.
• W2801456890 cites W2767748351 @default.
• W2801456890 cites W2793224908 @default.
• W2801456890 cites W2979608645 @default.
• W2801456890 doi "https://doi.org/10.3389/fonc.2018.00139" @default.
• W2801456890 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5937056" @default.
• W2801456890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29761078" @default.
• W2801456890 hasPublicationYear "2018" @default.
• W2801456890 type Work @default.
• W2801456890 sameAs 2801456890 @default.
• W2801456890 citedByCount "32" @default.
• W2801456890 countsByYear W28014568902019 @default.
• W2801456890 countsByYear W28014568902020 @default.
• W2801456890 countsByYear W28014568902021 @default.
• W2801456890 countsByYear W28014568902022 @default.
• W2801456890 countsByYear W28014568902023 @default.
• W2801456890 crossrefType "journal-article" @default.
• W2801456890 hasAuthorship W2801456890A5024273516 @default.
• W2801456890 hasAuthorship W2801456890A5037784199 @default.
• W2801456890 hasBestOaLocation W28014568901 @default.
• W2801456890 hasConcept C126322002 @default.
• W2801456890 hasConcept C143998085 @default.
• W2801456890 hasConcept C203014093 @default.
• W2801456890 hasConcept C2776694085 @default.
• W2801456890 hasConcept C2776755627 @default.
• W2801456890 hasConcept C2777589544 @default.
• W2801456890 hasConcept C2778191690 @default.

• next